The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for advanced, treatment-resistant melanoma when combined with nivolumab. The approval is based on trial data showing a 25% response rate with median durability of 14 months.